Evidence map›Paper›PMID 32555717›Full record

ArticlePloS one2020

Near-infrared photoimmunotherapy is effective treatment for colorectal cancer in orthotopic nude-mouse models.

Hannah M Hollandsworth, Siamak Amirfakhri, Filemoni Filemoni, Justin Molnar, Robert M Hoffman, Paul Yazaki, Michael Bouvet

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hannah M HollandsworthDepartment of Surgery, University of California San Diego, San Diego, CA, United States of America.ORCID 0000-0002-8867-6835
Siamak AmirfakhriDepartment of Surgery, University of California San Diego, San Diego, CA, United States of America.
Filemoni FilemoniDepartment of Surgery, University of California San Diego, San Diego, CA, United States of America.
Justin MolnarDepartment of Molecular Imaging and Therapy, Beckman Research Institute City of Hope, Los Angeles, CA, United States of America.
Robert M HoffmanDepartment of Surgery, University of California San Diego, San Diego, CA, United States of America.
Paul YazakiDepartment of Molecular Imaging and Therapy, Beckman Research Institute City of Hope, Los Angeles, CA, United States of America.
Michael BouvetDepartment of Surgery, University of California San Diego, San Diego, CA, United States of America.
University of California San Diego · USCity of Hope · US

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Development of Near Infrared Fluorescence-Guided Surgical Navigation and Tumor Specific Photoimmunotherapy for Improved Outcomes for GI CancersI01BX003856 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI BOUVET, MICHAEL · 2018 to 2022
–
CMA- Marker-assisted prevention and risk stratification (MAPRS): Mucin signatures and molecular imaging for the early detection of colorectal cancer.I01BX004494 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI BOUVET, MICHAEL · 2020 to 2023
–
BLRD VA I01 BX003856BLRD VA I01 BX004494NCI NIH HHS T32 CA121938
6 · The paper itself

Abstract

backgroundPhotoimmunotherapy (PIT) employs the use of a near-infrared (NIR) laser to activate an antibody conjugated to a NIR-activatable dye to induce cancer cell death. PIT has shown to be effective in a number of studies, however, there are no data on its use in colorectal cancer in an orthotopic model.

methodsHumanized anti-CEA antibody (M5A) was conjugated to NIR-activatable IRDye700DX (M5A-700). PIT was validated in vitro with a colon cancer cell-line, using a laser intensity of either 4 J/cm2, 8 J/cm2, or 16 J/cm2. Orthotopic colon cancer mouse models were established by surgical implantation of LS174T tumor fragments onto the cecum. M5A-700 was administered and PIT was performed 24 hours later using a 690 nm laser. Repeat PIT was performed after 7 days in one group. Control mice received laser treatment only.

resultsIn vitro PIT demonstrated tumor cell death in a laser intensity dose-dependent fashion. In orthotopic models, control mice demonstrated persistent tumor growth. Mice that underwent PIT one time had tumor growth arrested for one week, after which re-growth occurred. The group that received repeated PIT exposure had persistent inhibition of tumor growth.

conclusionPIT arrests tumor growth in colon cancer orthotopic nude-mouse models. Repeated PIT arrests colon cancer growth for a longer period of time. PIT may be a useful therapy in the future as an adjunct to surgical resection or as primary therapy to suppress tumor progression.

Indexed as

AnimalsCarcinogenesisCell Line, TumorColorectal NeoplasmsHumansImmunoconjugatesImmunotherapyIndolesMiceMice, NudeOrganosilicon CompoundsPhotosensitizing AgentsPhototherapyReceptors, Cell SurfaceTreatment OutcomeXenograft Model Antitumor Assayscarcinoembryonic antigen binding protein, humanImmunoconjugatesIndolesIRDye700DX N-hydroxysuccinimide esterOrganosilicon CompoundsPhotosensitizing AgentsReceptors, Cell Surface

Identifiers

PMID32555717
PMCPMC7302706
OpenAlexW3036318510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.